Clinical Trials
3 trialsNCT02943642 2026-05-18
Resimmune®
Virogen Biotechnology Inc.
Phase 2 Withdrawn
NCT03022565 2020-02-06
Vorinostat in Patients With Class 2 High Risk Uveal Melanoma
University of Miami
Phase EARLY_PHASE1 Withdrawn
NCT01386398 2015-01-21
Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Withdrawn